Tempus AI Raises $410M in IPO, Sees Revenue Surge
Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
- Latest
- Trending
Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
Senate subpoenas Novo's Langa over drug pricing; Jorgensen to testify in September as Novo blames U.S. health system for high ...
Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.
Swiss chemist Albert Hofmann first synthesized LSD in the 1930s. While research eventually halted, the drug is now being decriminalized ...
The US Court of Appeals ruled that forcing someone to use their biometrics to unlock a phone is not testimonial. ...
The Open Medical-LLM leaderboard offers valuable insights into AI-related medical devices, although none of the approved devices use generative AI.
The personalized DNA revolution falls short as a company's stock plummets by 90%. Valued at $3.5 billion, it seeks potential ...
Consider investing in AbbVie and e.l.f., two names with significant growth potential in 2024. AbbVie shines as a quality business ...
A lawsuit is underway as the misuse of #ivermectin as a COVID treatment continues. The article discusses the legal ramifications ...
Oxford University's DrugGPT, an AI tool to tackle prescription issues, could revolutionize healthcare, preventing mistakes, improving compliance, and reducing expenses.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.